# Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Canonical URL: https://biopharmsignal.com/news/ALT/altimmune-to-report-first-quarter-2026-financial-results-and-provide-business-up-e4890a75
Ticker: ALT
Company: Altimmune
Source: Altimmune
Published: 2026-05-06 11:30 EST
## Summary

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide...

## Article Body
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on May 13 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors .

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .

Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com

Media Contact: Real Chemistry altimmune@realchemistry.com
## Recent Company News
- 2026-07-28 11:00 EST — [Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder](https://biopharmsignal.com/news/ALT/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvi-1fc61fa7) — Source: Altimmune
- 2026-05-28 15:00 EST — [Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026](https://biopharmsignal.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mas-a943260b) — Source: Altimmune
- 2026-05-27 12:30 EST — [Altimmune to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-90ad12d9) — Source: Altimmune
- 2026-05-27 12:00 EST — [New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026](https://biopharmsignal.com/news/ALT/new-impact-phase-2b-data-highlight-concurrent-improvements-across-multiple-non-i-c3ed7d9e) — Source: Altimmune
- 2026-05-13 11:30 EST — [Altimmune Announces First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALT/altimmune-announces-first-quarter-2026-financial-results-and-business-update-8b5f5558) — Source: Altimmune
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)